| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
In astrocytes and hippocampal neurons, ethyl ferulate (1-50 μM) increases HO activity, HO-1 mRNA, and protein expression [1]. The meta-scaffold GOX senses cell death, and ethyl ferulate (5 μM, 12 hours) can safeguard generation neural cells by ethyl ferulate (10-50 μM, 24). Aβ-peptide (1-42) senses HO-1[1] and protects hippocampus nerves. ROS build-up, cytotoxicity, 3-NT production, and possible peroxidation [2]. The RPE cell workstation is shielded from the CoCl2 (150 µM)-induced reduction in cell viability by ethyl ferulate (20-160 µM, 24 hours) [5]. 40 μM of ethanol ferulate activates Nrf-2 and decreases RPE cells in a 24-hour period.
|
|---|---|
| ln Vivo |
Ethyl ferulate (15-50 mg/kg, i.p., twice a day for 5 days) reduces the acute pulmonary damage caused by LPS in mice[3].[4]. In a mouse model of oxygen-induced retinopathy, ethyl ferulate (0.05-0.2 μg, intravitreal injection, 1 µl/eye) suppresses retinal neovascularization[5].
|
| Cell Assay |
Western Blot analysis [5]
Cell Types: RPE cells (induced by 150 μM CoCl2 for 12 h) Tested Concentrations: 40 μM Incubation Duration: 2 h Experimental Results: Increased ROS production in Nrf- inhibited CoCl2-induced VEGFA expression [5]. 2 Expression and nuclear translocation. Keap-1 expression diminished, A and increased HO-1 and NQO-1 expression. Reduces hypoxia-induced HIF-1α and VEGFA expression. |
| Animal Protocol |
Animal/Disease Models: LPS (0.5 mg/kg)-induced acute lung injury mouse model [3]
Doses: 15 and 30 mg/, 1 µL/eye ) blocks major neovascularization in mouse models of oxygen-induced effects [5]. kg Route of Administration: intraperitoneal (ip) injection twice (two times) daily for 5 days Experimental Results: diminished leukocyte infiltration. MPO activity, mRNA levels, and secretion of TNF-α and IL-6 were diminished. |
| References |
|
| Additional Infomation |
Ethyl ferulate has been reported in Spiraea formosana, Coptis japonica, and other organisms with data available.
|
| Molecular Formula |
C12H14O4
|
|---|---|
| Molecular Weight |
222.2372
|
| Exact Mass |
222.089
|
| CAS # |
4046-02-0
|
| PubChem CID |
736681
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
382.3±0.0 °C at 760 mmHg
|
| Melting Point |
63-65 °C(lit.)
|
| Flash Point |
132.5±17.2 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.566
|
| LogP |
1.94
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
16
|
| Complexity |
249
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCOC(=O)/C=C/C1=CC(=C(C=C1)O)OC
|
| InChi Key |
ATJVZXXHKSYELS-FNORWQNLSA-N
|
| InChi Code |
InChI=1S/C12H14O4/c1-3-16-12(14)7-5-9-4-6-10(13)11(8-9)15-2/h4-8,13H,3H2,1-2H3/b7-5+
|
| Chemical Name |
ethyl (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~449.96 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.25 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.25 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (11.25 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4996 mL | 22.4982 mL | 44.9964 mL | |
| 5 mM | 0.8999 mL | 4.4996 mL | 8.9993 mL | |
| 10 mM | 0.4500 mL | 2.2498 mL | 4.4996 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
